{"pmid":32430287,"title":"Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.","text":["Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.","Pharmacol Res","Calo, Lorenzo A","Bertoldi, Giovanni","Davis, Paul A","32430287"],"journal":"Pharmacol Res","authors":["Calo, Lorenzo A","Bertoldi, Giovanni","Davis, Paul A"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32430287","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.phrs.2020.104903","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288375775233,"score":9.490897,"similar":[{"pmid":32374416,"title":"ACE2 and prognosis of COVID-19. Insights from Bartter's and Gitelman's syndromes patients.","text":["ACE2 and prognosis of COVID-19. Insights from Bartter's and Gitelman's syndromes patients.","The relationship between Renin-Angiotensin system (RAS) and COVID-19 pandemic and, in particular, RAS as part of the CoV-2 infection process via Angiotensin Converting Enzyme 2 (ACE2), the entry point of SARS-CoV-2, has resulted in conflicting suggestions regarding how RAS and its role(s) should inform treating COVID-19. ACE inhibitors or angiotensin II (Ang)-type 1 receptor blockers (ARBs), in fact, have been suggested to be avoided as they potentially upregulate ACE2 (1) and, conversely, there are suggestions that ARBs might be beneficial (2) as SARS-CoV-2 causing ACE2 downregulation slows the Ang II conversion to the vasodilatory, anti-inflammatory, antioxidant and antiatherosclerotic Ang 1-7 (3-5) , and the use of ARBs by blocking the excessive Ang II type-1 receptors activation, would be beneficial upregulating ACE2 activity and increasing Ang 1-7 levels. This article is protected by copyright. All rights reserved.","J Med Virol","Calo, Lorenzo A","Davis, Paul A","Rigato, Matteo","Sgarabotto, Luca","32374416"],"abstract":["The relationship between Renin-Angiotensin system (RAS) and COVID-19 pandemic and, in particular, RAS as part of the CoV-2 infection process via Angiotensin Converting Enzyme 2 (ACE2), the entry point of SARS-CoV-2, has resulted in conflicting suggestions regarding how RAS and its role(s) should inform treating COVID-19. ACE inhibitors or angiotensin II (Ang)-type 1 receptor blockers (ARBs), in fact, have been suggested to be avoided as they potentially upregulate ACE2 (1) and, conversely, there are suggestions that ARBs might be beneficial (2) as SARS-CoV-2 causing ACE2 downregulation slows the Ang II conversion to the vasodilatory, anti-inflammatory, antioxidant and antiatherosclerotic Ang 1-7 (3-5) , and the use of ARBs by blocking the excessive Ang II type-1 receptors activation, would be beneficial upregulating ACE2 activity and increasing Ang 1-7 levels. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Calo, Lorenzo A","Davis, Paul A","Rigato, Matteo","Sgarabotto, Luca"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374416","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25978","keywords":["ace2","bartter's syndrome","covid-19","gitelman's syndrome"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496354484224,"score":99.1506},{"pmid":32283223,"pmcid":"PMC7195000","title":"Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).","text":["Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).","Pharmacol Res","Abedi, Farshad","Rezaee, Ramin","Karimi, Gholamreza","32283223"],"journal":"Pharmacol Res","authors":["Abedi, Farshad","Rezaee, Ramin","Karimi, Gholamreza"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283223","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.phrs.2020.104808","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491438759938,"score":98.77674},{"pmid":32502097,"title":"Angiotensin-converting enzyme inhibitors, angiotensin II type 1 receptor blockers and risk of COVID 19: information from Bartter's and Gitelman's syndromes patients.","text":["Angiotensin-converting enzyme inhibitors, angiotensin II type 1 receptor blockers and risk of COVID 19: information from Bartter's and Gitelman's syndromes patients.","J Hypertens","Calo, Lorenzo A","Davis, Paul A","Rigato, Matteo","Sgarabotto, Luca","32502097"],"journal":"J Hypertens","authors":["Calo, Lorenzo A","Davis, Paul A","Rigato, Matteo","Sgarabotto, Luca"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502097","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1097/HJH.0000000000002495","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668804508742844417,"score":85.716},{"pmid":32456368,"title":"[Therapy of coronavirus disease 2019 induced acute respiratory distress syndrome is different from traditional acute respiratory distress syndrome].","text":["[Therapy of coronavirus disease 2019 induced acute respiratory distress syndrome is different from traditional acute respiratory distress syndrome].","Coronavirus disease 2019 (COVID-19) has become a global public health emergency threatening people's lives around the world. Although the acute respiratory distress syndrome (ARDS) induced by COVID-19 is similar to the ARDS caused by other diseases in terms of pathophysiological basis and clinical manifestations, they are also different in many aspects, which lead to different clinical therapies. Therefore, understanding the differences and similarities of ARDS induced by COVID-19 and other diseases currently are the basis for clinicians to make decisions for the treatment of COVID-19 induced ARDS.","Zhonghua Shao Shang Za Zhi","Pan, C","Xie, J F","Qiu, H B","Yang, Y","32456368"],"abstract":["Coronavirus disease 2019 (COVID-19) has become a global public health emergency threatening people's lives around the world. Although the acute respiratory distress syndrome (ARDS) induced by COVID-19 is similar to the ARDS caused by other diseases in terms of pathophysiological basis and clinical manifestations, they are also different in many aspects, which lead to different clinical therapies. Therefore, understanding the differences and similarities of ARDS induced by COVID-19 and other diseases currently are the basis for clinicians to make decisions for the treatment of COVID-19 induced ARDS."],"journal":"Zhonghua Shao Shang Za Zhi","authors":["Pan, C","Xie, J F","Qiu, H B","Yang, Y"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32456368","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3760/cma.j.cn501120-20200407-00214","keywords":["acute respiratory distress syndrome","coronavirus disease 2019","immunomodulation","mechanical ventilation","original disease"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668141322611982336,"score":71.99588},{"pmid":32442317,"title":"The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).","text":["The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).","COVID-19, the disease resulting from infection by a novel coronavirus: SARS-Cov2 that has rapidly spread since November 2019 leading to a global pandemic. SARS-Cov2 has infected over 4 million people and caused over 290,000 deaths worldwide. Although most cases are mild, a subset of patients develop a severe and atypical presentation of Acute Respiratory Distress Syndrome (ARDS) that is characterised by a cytokine release storm (CRS). Paradoxically, treatment with anti-inflammatory agents and immune regulators has been associated with worsening of ARDS. We hypothesize that the intrinsic circadian clock of the lung and the immune system may regulate individual components of CRS and thus chronotherapy may be used to effectively manage ARDS in COVID-19 patients.","Br J Pharmacol","Tamimi, Faleh","Abusamak, Mohammad","Akkanti, Bindu","Chen, Zheng","Yoo, Seung-Hee","Karmouty-Quintana, Harry","32442317"],"abstract":["COVID-19, the disease resulting from infection by a novel coronavirus: SARS-Cov2 that has rapidly spread since November 2019 leading to a global pandemic. SARS-Cov2 has infected over 4 million people and caused over 290,000 deaths worldwide. Although most cases are mild, a subset of patients develop a severe and atypical presentation of Acute Respiratory Distress Syndrome (ARDS) that is characterised by a cytokine release storm (CRS). Paradoxically, treatment with anti-inflammatory agents and immune regulators has been associated with worsening of ARDS. We hypothesize that the intrinsic circadian clock of the lung and the immune system may regulate individual components of CRS and thus chronotherapy may be used to effectively manage ARDS in COVID-19 patients."],"journal":"Br J Pharmacol","authors":["Tamimi, Faleh","Abusamak, Mohammad","Akkanti, Bindu","Chen, Zheng","Yoo, Seung-Hee","Karmouty-Quintana, Harry"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442317","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bph.15140","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667535119453257728,"score":68.63925}]}